Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/systems-biology-in-biotech-pharma-development-in-vivo-pharmacology-UQ9xKh00PO
References (25)
-
Andrew Johnson, Danxin Wang, W. Sadee (2005)
Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.Pharmacology & therapeutics, 106 1
-
Qian Ding, L. Gan (2012)
Conditional control of gene expression in the mouse retina.Methods in molecular biology, 884
-
D. Nebert, Lucia Jorge-Nebert, E. Vesell (2003)
Pharmacogenomics and “Individualized Drug Therapy”American Journal of Pharmacogenomics, 3
-
Guochun Liao, Xun Zhang, D. Clark, G. Peltz (2008)
A Genomic “Roadmap” to “Better” DrugsDrug Metabolism Reviews, 40
-
Qing Yan (2008)
The integration of personalized and systems medicine: bioinformatics support for pharmacogenomics and drug discovery.Methods in molecular biology, 448
-
Kristina Thiel, P. Giangrande (2010)
Intracellular delivery of RNA-based therapeutics using aptamers.Therapeutic delivery, 1 6
-
I. Blagbrough, C. Zara (2008)
Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery StrategiesPharmaceutical Research, 26
-
Jiehua Zhou, J. Rossi (2011)
Aptamer-targeted RNAi for HIV-1 therapy.Methods in molecular biology, 721
-
Y. Gondo (2008)
Trends in large-scale mouse mutagenesis: from genetics to functional genomicsNature Reviews Genetics, 9
-
S. Brown, John Hancock (2006)
The mouse genome.Genome dynamics, 2
-
R. Simon (2008)
The Use of Genomics in Clinical Trial DesignClinical Cancer Research, 14
-
Sean Ekins, Jordi Mestres, B. Testa (2007)
In silico pharmacology for drug discovery: methods for virtual ligand screening and profilingBritish Journal of Pharmacology, 152
-
S. Kissler, L. Parijs (2004)
Exploring the genetic basis of disease using RNA interferenceExpert Review of Molecular Diagnostics, 4
-
A. Daly (2007)
Individualized drug therapy.Current opinion in drug discovery & development, 10 1
-
L. Shultz, F. Ishikawa, D. Greiner (2007)
Humanized mice in translational biomedical researchNature Reviews Immunology, 7
-
D. Tomalik‐Scharte, A. Lazar, U. Fuhr, J. Kirchheiner (2008)
The clinical role of genetic polymorphisms in drug-metabolizing enzymesThe Pharmacogenomics Journal, 8
-
L. Sheiner (1997)
Learning versus confirming in clinical drug developmentClinical Pharmacology & Therapeutics, 61
-
V. Patzel (2007)
In silico selection of active siRNA.Drug discovery today, 12 3-4
-
R. Colombo, J. Moll (2012)
Target Validation to Biomarker DevelopmentMolecular Diagnosis & Therapy, 12
-
Yingying Guo, S. Shafer, P. Weller, J. Usuka, G. Peltz (2005)
Pharmacogenomics and drug development.Pharmacogenomics, 6 8
-
S. Ekins, J. Mestres, B. Testa (2007)
In silico pharmacology for drug discovery: applications to targets and beyondBritish Journal of Pharmacology, 152
-
M. Fielden, J. Matthews, K. Fertuck, R. Halgren, T. Zacharewski (2002)
In Silico Approaches to Mechanistic and Predictive Toxicology: An Introduction to Bioinformatics for ToxicologistsCritical Reviews in Toxicology, 32
-
S. Michelson (2006)
The impact of systems biology and biosimulation on drug discovery and development.Molecular bioSystems, 2 6-7
-
D. Noble (2001)
The future: putting Humpty-Dumpty together again.Biochemical Society transactions, 31 Pt 1
-
A. Reynolds, D. Leake, Q. Boese, S. Scaringe, W. Marshall, A. Khvorova (2004)
Rational siRNA design for RNA interferenceNature Biotechnology, 22
- Publisher
- Springer Netherlands
- Copyright
- © The Author(s) 2012
- ISBN
- 978-94-007-2848-6
- Pages
- 69 –76
- DOI
- 10.1007/978-94-007-2849-3_6
- Publisher site
- See Chapter on Publisher Site
Abstract
[This chapter covers qualitative in vivo approaches in animals and man, which will help to develop in silico pharmacology and PK positions. Additionally, we cover RNA interference in this chapter even though it is largely an in vitro method for characterizing the dynamics of cell physiology. And though in silico pharmacology is only in a rudimentary state, it is vitally important for clinical model based drug design (MBDD) development (see Chap. 10).]
Published: Jan 4, 2012
Keywords: Humanize Mouse; Animal Disease Model; Xenobiotic Receptor; Virtual Ligand Screening; Adaptive Trial Design